Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Placebo-Controlled Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease

Next Previous
Trial Profile

Double-Blind, Placebo-Controlled Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Transcrocetinate sodium (Primary)
  • Indications Hypoxia; Interstitial lung diseases
  • Focus Therapeutic Use
  • Acronyms DLCO; ILD-DLCO
  • Sponsors Diffusion Pharmaceuticals

Most Recent Events

  • 08 Aug 2022 Status changed from recruiting to discontinued. Reason the study was stopped:Due to, among other things, positive results from the 200-302 trial, the trial has been terminated early. Resources shifted to new 200-208 GBM trial using information gained from200-302.
  • 12 May 2022 According to a Diffusion Pharmaceuticals media release, enrollment of this study continued during the first quarter of 2022. The Company currently anticipates completing dosing in the second half of 2022 and reporting topline results within two months of study completion.
  • 21 Mar 2022 According to a Diffusion Pharmaceuticals media release, dosing is expected to be completed in mid-2022 and topline results reported within two months of study completion.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top